1. The Dawn of a New Era of Alzheimer’s Research and Drug Development

   • Y. Hara
   • Howard M. Fillit

   Editorial 01 July 2022 Pages: 385 - 386

2. The Clinical Trials Alzheimer’s Disease (CTAD) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!

   • Michael W. Weiner

   Editorial 04 July 2022 Pages: 387 - 387

3. Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report

   • Rema Raman
   • P. Aisen
   • CTAD Task Force

   CTAD Task Force Paper Open access 13 May 2022 Pages: 388 - 392

4. The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report

   • Julien Delrieu
   • R. J. Bateman
   • J. Cummings

   CTAD Task Force Paper Open access 16 May 2022 Pages: 393 - 399

   

5. Prediction of Cognitive Decline for Enrichment of Alzheimer’s Disease Clinical Trials

   • A. Tam
   • C. Laurent
   • Alzheimer’s Disease Neuroimaging Initiative

   Original Research 05 May 2022 Pages: 400 - 409

   

6. Effects of Non-Invasive Brain Stimulation on Alzheimer’s Disease

   • Lihua Gu
   • H. Xu
   • F. Qian

   Original Research 22 April 2022 Pages: 410 - 424

   

7. Evaluation of the Feasibility, Safety and Efficacy of the Use of Intravenous Infusions of Adenosine Triphosphate (ATP) in People Affected by Moderate to Severe Alzheimer’s Disease: A Double-Blind Masked Clinical Trial for Dose Finding

   • Agustín Ruiz
   • D. Sánchez
   • M. Boada

   Original Research 22 April 2022 Pages: 425 - 434

   

8. Subjective Cognitive Decline in a Registry Sample: Relation to Psychiatric History, Loneliness, and Personality

   • Gretchen O. Reynolds
   • L. Manning
   • R. E. Amariglio

   Original Research 24 March 2022 Pages: 435 - 440

9. Increased Incident Alzheimer’s Disease among Individuals with Varicose Veins: A Population-Based Cohort Study

   • Chun-Yu Cheng

   Original Research 04 February 2022 Pages: 441 - 448

   

10. Association between Dietary Theobromine and Cognitive Function in a Representative American Population: A Cross-Sectional Study

    • L. Gao
    • W. Ge
    • Li He

    Original Research 22 April 2022 Pages: 449 - 457

    

11. Mesenchymal Stem Cells Modulate SIRT1/MiR-134/GSK3β Signaling Pathway in a Rat Model of Alzheimer’s Disease

    • O. A. R. Abozaid
    • M. W. Sallam
    • Esraa S. A. Ahmed

    Original Research Open access 18 February 2022 Pages: 458 - 468

    

12. A Conformational Variant of p53 (U-p53^AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer’s Disease

    • Simona Piccirella
    • L. Van Neste
    • P. Kinnon

    Original Research Open access 17 May 2022 Pages: 469 - 479

    

13. Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats

    • B. Souchet
    • M. Audrain
    • Jérôme Braudeau

    Original Research 25 January 2022 Pages: 480 - 490

    

14. Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer’s Disease from Frontotemporal Lobar Degeneration

    • Marion Ortner
    • O. Goldhardt
    • T. Grimmer

    Original Research Open access 04 March 2022 Pages: 491 - 498

    

15. Decreased Gray—White Matter Contrast of [¹¹C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea

    • S. Ylä-Herttuala
    • M. Hakulinen
    • Esa Mervaala

    Original Research Open access 07 February 2022 Pages: 499 - 506

    

16. Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease

    • Sharon Cohen
    • J. Cummings
    • J. Harrison

    Review Open access 26 April 2022 Pages: 507 - 522

    

17. Aging, Senescence, and Dementia

    • Q. Behfar
    • A. Ramirez Zuniga
    • Pamela V. Martino-Adami

    Review 28 April 2022 Pages: 523 - 531

    

18. Clinical Research Investigating Alzheimer’s Disease in China: Current Status and Future Perspectives Toward Prevention

    • Q. Wang
    • F. Gao
    • Yong Shen

    Review 28 April 2022 Pages: 532 - 541

19. Site Readiness Framework to Improve Health System Preparedness for a Potential New Alzheimer’s Disease Treatment Paradigm

    • M. Anderson
    • N. Sathe
    • R. Christopher

    Brief Report Open access 01 April 2022 Pages: 542 - 549

    

20. What Matters to Patients with Alzheimer’s Disease and Their Care Partners? Implications for Understanding the Value of Future Interventions

    • F. Jessen
    • J. Georges
    • Samantha Benham-Hermetz

    Brief Report Open access 02 February 2022 Pages: 550 - 555

21. Standardizing Electronic Health Record Data on AD/ADRD to Accelerate Health Equity in Prevention, Detection, and Treatment

    • C. G. Lyketsos
    • S. B. Roberts
    • J. G. Haaga

    Brief Report 02 May 2022 Pages: 556 - 560

22. Early-Onset Type 2 Diabetes and Risk of Dementia

    • Tomoyuki Kawada

    Letter to the Editor 28 April 2022 Pages: 561 - 561

23. Reply to Letter to the Editor: “Early-Onset Type 2 Diabetes and Risk of Dementia”

    • K. Wang
    • Hong Liu

    Reply to Letter to the Editor 28 April 2022 Pages: 562 - 562